Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.
|
30654457 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
|
31699991 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous study demonstrated that HDAC inhibitor phenylbutyrate (PB) could induce AML1-ETO positive leukemia cell line Kasumi-1 cells to undergo differentiation and apoptosis accompanied by significant changes in gene expression profile.
|
29518627 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that RUNX1/ETO maintains leukemia by promoting cell cycle progression and identifies G1 CCND-CDK complexes as promising therapeutic targets for treatment of RUNX1/ETO-driven AML.
|
30300583 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that miR-130a is directly activated by AML1/ETO, and may act as a factor which is associated with leukemia burden, event-free survival, and chemotherapy sensitivity in t(8;21) AML.
|
29493383 |
2018 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Disruption of VPS13B may thus cause the unusual features of RUNX1-RUNX1T1 leukemia.
|
29264741 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Remarkable progress has been achieved in understanding the molecular pathogenesis of AML1-ETO leukemia.
|
28299657 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A hematological cancer panel assay indicated that EZH1/2 dual inhibitor has efficacy against some lymphomas, multiple myeloma, and leukemia with fusion genes such as MLL-AF9, MLL-AF4, and AML1-ETO.
|
28741798 |
2017 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the RUNX1-RUNX1T1 (AML1-ETO) fusion.
|
28516957 |
2017 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Areas covered: Available techniques include multi-color flow cytometry (MFC) of leukemia associated immunophenotypes (LAIP), quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) for detecting fusion and mutated genes (RUNX1-RUNX1T1, CBFB-MYH11, and NPM1), overexpression of genes such as WT1, and next generation sequencing (NGS) for MRD.
|
28475434 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of STUB1 could be a promising therapeutic strategy for RUNX1-RUNX1T1 leukemia.
|
28536267 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PAR-1 deficiency also reduced leukemogenicity of AML1-ETO-induced leukemia.
|
27819671 |
2017 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.
|
28043811 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia.
|
27144550 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.
|
27346355 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our previous study, we showed that APP is highly expressed and regulates leukemia cell migration in AML1‑ETO-positive (AE) leukemia.
|
27460334 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To better define the genetic landscape in AML and distinguish driver from passenger mutations, we compared the mutational profiles of AML1-ETO-driven mouse models of leukemia with the mutational profiles of human AML patients.
|
26666262 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study reveals a role of CBL in restricting myeloid proliferation of human AML1-ETO-induced leukemia, and identifies UBASH3B/Sts-1 as a potential target for pharmaceutical intervention.
|
26449661 |
2016 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, Wnt/β-catenin signaling induces transcription and translocation of RUNX1 and ETO fusion gene partners, opening a novel window to understand the onset/development of leukemia.
|
26333776 |
2015 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies showed that Drosophila provides a genuine model to study how AML1-ETO promotes leukemia.
|
24342949 |
2014 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We successfully established a mouse model of human leukemia by transplanting bone marrow cells co-transfected with the K-ras (G12D) mutation and AML1/ETO fusion protein.
|
24480914 |
2014 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This translocation causes expression of the RUNX1-ETO (AML1-ETO) fusion protein, which cooperates with additional mutations in leukemia development.
|
23772668 |
2014 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1-ETO is thought to promote leukemia development through the aberrant regulation of RUNX1 (AML1) target genes.
|
24130502 |
2013 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By focusing on the anti-apoptotic gene Bcl-2, the key regulator gene of granulocytic differentiation CCAAT/enhancer-binding protein α (CEBPA) and the tumor suppressor gene p14(ARF), we found that both AML1-ETO-expressing cell lines and t(8;21) leukemia samples displayed low levels of these three genes.
|
23673926 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the expression of the fusion genes CBFB/MYH11 or RUNX1/RUNX1T1 alone is not sufficient to cause leukemia, we performed exome sequencing of an AML sample with an inv(16) to identify mutations, which may collaborate with the CBFB/MYH11 fusion during leukemogenesis.
|
23878140 |
2013 |